No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
STTK240621P2500
- 0.05
- 0.000.00%
15min DelayTrading Apr 29 09:41 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume100 Open Interest2.50Strike Price0.00Turnover608.51%IV42.89%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0592Delta0.0704Gamma85.80Leverage Ratio-0.0476Theta0.0000Rho-5.08Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
H.C. Wainwright Maintains Shattuck Labs(STTK.US) With Buy Rating, Cuts Target Price to $16
H.C. Wainwright analyst Joseph Pantginis maintains $Shattuck Labs(STTK.US)$ with a buy rating, and adjusts the target price from $28 to $16.According to TipRanks data, the analyst has a success rate o
Shattuck Labs Is Maintained at Buy by HC Wainwright & Co.
Shattuck Labs Is Maintained at Buy by HC Wainwright & Co.
Express News | Shattuck Labs Inc : H.c. Wainwright Cuts Target Price to $16 From $28
HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis maintains Shattuck Labs (NASDAQ:STTK) with a Buy and lowers the price target from $28 to $16.
Shattuck Labs Is Maintained at Buy by Citigroup
Shattuck Labs Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Shattuck Labs, Lowers Price Target to $9
Comments
$Shattuck Labs(STTK.US$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
1
$Shattuck Labs(STTK.US$ Benzinga· 2 mins ago
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
1
$Shattuck Labs(STTK.US$
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
1
$Shattuck Labs(STTK.US$ Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
Read more